Personalis

Historical price data

Personalis is on a mission to transform cancer management through its industry-leading, ultra-sensitive NeXT Platform for ctDNA detection and MRD monitoring. The company has successfully pivoted from population genomics to focus on the high-growth oncology diagnostics market, securing key partnerships and commercial traction. Its strategy centers on establishing its NeXT Personal® test as the standard for MRD assessment while expanding into adjacent opportunities in therapy selection and immuno-oncology biomarker profiling to drive long-term growth.

The NeXT Platform® is a proprietary, ultra-sensitive genomic profiling system for circulating tumor DNA detection, enabling molecular residual disease monitoring and comprehensive therapy selection from a single blood draw.

Personalis competes in MRD with leaders like Natera (Signatera) and Guardant Health (Reveal), differentiating primarily on superior sensitivity and genomic breadth. In therapy selection, it faces entrenched players like Guardant and Foundation Medicine. Its technological edge is clear, but commercial execution is the key challenge.